Illinois Municipal Retirement Fund Buys 25,585 Shares of Elanco Animal Health Incorporated $ELAN

Posted by Francis Steltz on Jul 21st, 2026

Illinois Municipal Retirement Fund increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN – Free Report) by 49.5% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 77,279 shares of the company’s stock after purchasing an additional 25,585 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in Elanco Animal Health were worth $1,849,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ELAN. T. Rowe Price Investment Management Inc. boosted its stake in Elanco Animal Health by 11.8% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 35,227,418 shares of the company’s stock worth $797,197,000 after purchasing an additional 3,717,404 shares during the period. Dimensional Fund Advisors LP grew its holdings in Elanco Animal Health by 1.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 25,082,545 shares of the company’s stock valued at $567,622,000 after buying an additional 373,869 shares in the last quarter. UBS Group AG increased its position in shares of Elanco Animal Health by 56.7% during the third quarter. UBS Group AG now owns 16,468,148 shares of the company’s stock valued at $331,669,000 after buying an additional 5,961,457 shares during the period. Geode Capital Management LLC increased its position in shares of Elanco Animal Health by 7.3% during the fourth quarter. Geode Capital Management LLC now owns 9,425,533 shares of the company’s stock valued at $213,343,000 after buying an additional 640,098 shares during the period. Finally, Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Elanco Animal Health by 16.1% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 5,771,622 shares of the company’s stock worth $130,612,000 after buying an additional 799,745 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Stock Down 2.5%

Shares of NYSE:ELAN opened at $25.18 on Tuesday. Elanco Animal Health Incorporated has a 52-week low of $13.39 and a 52-week high of $27.72. The firm has a fifty day moving average of $23.70 and a 200 day moving average of $23.91. The firm has a market capitalization of $12.57 billion, a PE ratio of -50.35, a price-to-earnings-growth ratio of 1.69 and a beta of 1.68. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16.

Elanco Animal Health (NYSE:ELAN – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter last year, the business posted $0.37 earnings per share. The company’s revenue for the quarter was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, research analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current fiscal year.

Insider Transactions at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons bought 4,971 shares of the business’s stock in a transaction on Friday, May 15th. The stock was acquired at an average price of $20.09 per share, with a total value of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares in the company, valued at $3,454,897.39. This represents a 2.98% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Rajeev A. Modi purchased 4,911 shares of Elanco Animal Health stock in a transaction on Friday, May 15th. The shares were acquired at an average price of $20.35 per share, for a total transaction of $99,938.85. Following the completion of the transaction, the insider directly owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. The trade was a 3.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Company insiders own 1.14% of the company’s stock.

Analyst Upgrades and Downgrades

ELAN has been the subject of a number of analyst reports. Citigroup raised their price objective on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th. Wall Street Zen downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 24th. Weiss Ratings downgraded shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday, May 11th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $28.55.

Get Our Latest Research Report on Elanco Animal Health

Elanco Animal Health Company Profile

(Free Report)

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.